Crofelemer Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 125 mg
Reference Brands: Fulyzaq (USA)
Category:
Gastrointestinal Drugs
Crofelemer is available in Tablets
and strengths such as 125 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Crofelemer is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Crofelemer can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Crofelemer is a plant-derived antidiarrheal agent obtained from the red sap of the South American tree Croton lechleri. It is specifically used for the management of noninfectious diarrhea in HIV-positive patients who are receiving antiretroviral therapy. By acting locally within the gastrointestinal tract, crofelemer helps reduce excess fluid secretion in the intestines, providing symptomatic relief without affecting normal gut motility.
During therapy, crofelemer has been associated with occasional, mild elevations in serum liver enzymes. However, it has not been linked to cases of clinically apparent acute liver injury, making it a well-tolerated option when used under appropriate medical supervision. Its localized mechanism of action allows long-term use for symptom control in eligible patients.
Crofelemer is not intended for the treatment of infectious diarrhea caused by bacteria, viruses, or parasites, as it addresses symptoms rather than underlying infections. The drug was initially developed by Napo Pharmaceuticals, a wholly owned subsidiary of Jaguar Health, Inc. Today, crofelemer remains an important therapeutic option for improving quality of life in patients experiencing chronic, noninfectious diarrhea related to antiretroviral treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing